LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Nektar Therapeutics

Avatud

0.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.68

Max

0.72

Põhinäitajad

By Trading Economics

Sissetulek

44M

7.3M

Müük

5.1M

29M

Aktsiakasum

-0.24

Kasumimarginaal

24.888

Töötajad

61

EBITDA

48M

17M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+592.96% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-35M

133M

Eelmine avamishind

0.71

Eelmine sulgemishind

0.71

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2025, 23:20 UTC

Tulu

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. mai 2025, 22:58 UTC

Tulu

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. mai 2025, 22:37 UTC

Tulu

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. mai 2025, 22:36 UTC

Tulu

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. mai 2025, 22:35 UTC

Tulu

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. mai 2025, 22:34 UTC

Tulu

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. mai 2025, 22:30 UTC

Tulu

Aristocrat Interim Dividend 44 Australian Cents/Share

13. mai 2025, 22:30 UTC

Tulu

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. mai 2025, 22:29 UTC

Tulu

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. mai 2025, 22:28 UTC

Tulu

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. mai 2025, 21:15 UTC

Tulu

Nu Holdings 1Q Rev $3.2B >NU

13. mai 2025, 21:03 UTC

Peamised uudised

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. mai 2025, 20:32 UTC

Tulu

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. mai 2025, 20:31 UTC

Tulu

Alcon 1Q Sales $2.45B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q Rev $2.47B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q EPS 70c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

592.96% tõus

12 kuu keskmine prognoos

Keskmine 4.92 USD  592.96%

Kõrge 7 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

6

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.